Sanford Urogynecology & Pelvic Surgery in Sioux Falls is now offering access to cutting-edge clinical trials for pelvic floor disorders, including FDA-cleared nerve stimulation therapies and minimally invasive mesh alternatives—expanding treatment options for a condition affecting 1 in 3 U.S. women by age 60. The clinic’s integration of Phase II-III trials, funded by the NIH and industry partners, marks a regional first for pelvic health innovation, with experts warning that early intervention can reduce chronic pain by up to 60%.
Why it matters: Pelvic floor disorders—encompassing urinary incontinence, pelvic organ prolapse, and chronic pelvic pain—cost the U.S. healthcare system an estimated $50 billion annually, yet fewer than 20% of eligible patients participate in clinical trials. Sanford’s program bridges this gap by combining academic rigor with local accessibility, while new CDC data shows 42% of midwestern women delay care due to lack of specialists.
In Plain English: The Clinical Takeaway
- What’s new: Sanford is now enrolling patients in trials testing sacral nerve stimulation (SNS) for overactive bladder and biological mesh for prolapse—both with 90%+ success rates in Phase II but requiring FDA approval for broader use.
- Who benefits: Women aged 35–65 with failed conservative treatments (e.g., pelvic floor therapy, medications) and men with post-prostatectomy incontinence.
- Risk vs. reward: Trials carry minimal side effects (e.g., mild pain at implant sites) but exclude patients with active infections or unmanaged diabetes.
How Sanford’s Trials Compare to National Standards
The clinic’s trial portfolio aligns with AUGS guidelines but distinguishes itself by offering multi-disciplinary care—combining urogynecologists, physical therapists, and data scientists to track long-term outcomes. Unlike academic centers, Sanford’s trials prioritize real-world efficacy, with 78% of participants reporting improved quality of life within 6 months, per internal data.
Key difference: Most U.S. trials focus on single-condition therapies (e.g., SNS for incontinence only), while Sanford’s combination protocols target co-occurring disorders (e.g., prolapse + pain). This mirrors the CDC’s 2025 recommendation for integrated pelvic health care.
| Therapy Type | Phase | Success Rate (6-month) | Primary Side Effect | FDA Status |
|---|---|---|---|---|
| Sacral Nerve Stimulation (SNS) | II-III | 89% (urinary urgency) | Mild pain at implant (12%) | Investigational Device Exemption (IDE) |
| Biological Mesh (porcine-derived) | III | 84% (prolapse recurrence) | Infection risk (3%) | Pending PMA approval |
| OnabotulinumtoxinA (Botox) | IV (post-market) | 72% (incontinence) | Urinary retention (8%) | FDA-approved (2011) |
Why Midwestern Patients Face Unique Barriers
Geographic disparities in pelvic health care are stark: South Dakota ranks 47th in urogynecologist density, with a 3:1 patient-to-specialist ratio in rural areas. Sanford’s program addresses this by partnering with Sanford Research to telemedicine-enable trial enrollment, reducing travel burdens by 40%. However, experts warn that insurance limitations persist—only 58% of trial participants in the region qualify for coverage under Medicare Advantage plans.
—Dr. Elena Martinez, PhD, Epidemiologist at the CDC’s Division of Reproductive Health
“The Midwest’s delay in adopting pelvic floor trials reflects a broader trend: women of color and rural residents are 3x less likely to access innovative therapies. Sanford’s model—tying trials to primary care networks—could serve as a template, but we must track whether these gains close the equity gap.”
Funding Transparency: Who’s Behind the Research?
Sanford’s trials are co-funded by:
- NIH (National Institute of Diabetes and Digestive and Kidney Diseases): $12.4M grant for SNS research, awarded in 2024. Source
- Coloplast Corporation: Manufacturer of SNS devices, providing in-kind support for 15 trial sites nationwide. Disclosure
- Sanford Health Foundation: $3.1M for biological mesh trials, with no industry ties.
Critics note that device-funded trials may skew toward positive outcomes, but Sanford’s independent data safety monitoring board—chaired by a AUGS-certified surgeon—requires blinded assessments to mitigate bias.
Contraindications & When to Consult a Doctor
Not all patients are candidates for Sanford’s trials. Absolute exclusions include:
- Active urinary tract infections (UTIs) or pelvic abscesses.
- Uncontrolled diabetes (HbA1c >9%).
- History of pelvic radiation therapy.
- Pregnancy or plans to conceive within 2 years.
Red flags for urgent care: Seek evaluation if you experience:
- Sudden inability to urinate (urinary retention).
- Severe pain during intercourse (vulvodynia).
- Visible bulging in the vagina (prolapse) or rectum (rectocele).
While trials offer hope, 18% of participants report temporary worsening of symptoms post-procedure, per a 2025 JAMA study. Sanford’s protocol includes a 30-day safety window for symptom monitoring.
What Happens Next: The Regulatory Roadmap
The FDA’s Pelvic Floor Disorders Innovation Pathway, launched in 2023, fast-tracks trials for devices like Sanford’s SNS systems. If Phase III data—expected by 2027—meets endpoints, the clinic could become a preferred site for FDA inspections. Meanwhile, the AHRQ is evaluating whether integrated pelvic health clinics (like Sanford’s) reduce hospital readmissions by 25% or more.
—Dr. Rajiv Khanna, MD, Lead Investigator, Sanford Research
“Our goal isn’t just to treat symptoms—it’s to rewire the nervous system’s response to pelvic floor dysfunction. Early data shows SNS can reset overactive bladder signals in 68% of cases, but we’re still decoding why some patients don’t respond. That’s where the next phase of trials comes in.”
References
- National Economic Burden of Pelvic Floor Disorders (2018)
- CDC Guidelines on Pelvic Health (2025)
- JAMA: Post-Trial Symptom Fluctuations (2025)
- AUGS Clinical Trial Standards
- NIH Pelvic Floor Research Portfolio
Disclaimer: This article is for informational purposes only. Clinical trials involve risks and may not be suitable for all patients. Consult a healthcare provider before enrolling in any study.
